Novo CEO: Obesity goal within touching distance well before 2025 deadline
Novo Nordisk may be able to realize its ambition to double the size of its obesity business compared to 2019 levels three years early. A new target may be revealed soon.
by marketwire, translated by catherine brett
Danish pharmaceutical giant Novo Nordisk is well on the way to achieving its 2025 goal for sales of weight loss drugs three years early. There is therefore a good chance that a new target will be revealed at the company’s upcoming capital markets day, on March 3.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Obesity business grows at Novo Nordisk despite Wegovy woes
For subscribers
